Congratulations to Yunkang Group Ltd. (2325.HK) on its Successful Listing

Yunkang Group Ltd. has been successfully listed on the Mainboard of HKSE on 18 May 2022. AVISTA Group is honored to be engaged in providing valuation services.

Yunkang Group is a medical operation service provider in China established in 2008, primarily engaged in offering a full suite of diagnostic testing services for medical institutions. The group was among the top five major medical operation service providers in China in 2020, with a market share of 3.7% in terms of revenue, according to Frost & Sullivan.

Yunkang also ranked the second largest provider in China’s diagnostic testing services for medical institution alliances market in 2020, accounted for a 12.5% market share.

The outbreak of the COVID-19 pandemic, and the subsequent growth in market needs for diagnostic services and supplies, the COVID-19 test kits in particular, have contributed to a surge in demand for Yunkang’s diagnostic outsourcing services, presenting a higher gross-profit margin accompanied by economies of scale.

Located in a diagnostic outsourcing service market with sizable growth potential, and equipped with own reliable diagnostic capabilities and a nationwide customer base, currently Yunkang operates three lines of business, namely diagnostic testing services for medical institution alliances, diagnostic outsourcing services and diagnostic testing services via outpatient clinic for non-medical institution customers. The group targets to continue expanding its on-site diagnostic center network to capture a larger market share.

Date: 18 May 2022 | Tags: Business Valuation